Osmotic delivery device comprising an insulinotropic peptide and uses thereof
AssigneeIntarcia Therapeutics, Inc.
InventorsThomas R Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
Life of this patent
Estimating the term…
Loading patent…
AssigneeIntarcia Therapeutics, Inc.
InventorsThomas R Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
Estimating the term…
A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
-21. (canceled)
A method of manufacturing an osmotic delivery device comprising, loading a suspension formulation into a reservoir of the osmotic delivery device,
The method of claim 37, wherein the buffer is citrate.
Dependencies are inferred from the claim text.